Moreover, FDA-approved DNA hypomethylating agents (DHAs) such as decitabine (DAC) and 5-azacytidine (5AC), widely used in acute myeloid leukemia (AML), have been shown to selectively activate SIRT6 enzymatic activity without significantly affecting other sirtuin isoforms. Here, SIRT6 is linked to acute myeloid leukemia.